Le Lézard
Classified in: Health, Covid-19 virus
Subjects: PDT, PSF

Cordant Offers Telemedicine Solution for Drug Testing to Help Provide Critical Care to Addiction and Mental Health Patients During COVID-19 Pandemic


DENVER, April 8, 2020 /PRNewswire/ -- Cordant Health Solutions® (Cordant) offers a video-observed oral fluid drug testing solution ideal for addiction treatment organizations and government agencies to help continue to provide critical care to individuals recovering from substance use disorder. Oral fluid testing is an effective tool that has been recognized as an appropriate matrix for testing in addiction treatment settings, according to the American Society of Addiction Medicine.

Due to widespread "shelter-in-place" orders, and to minimize exposure to COVID-19, many clinicians and government agencies are struggling to maintain their treatment protocols and programs. While many may already offer telemedicine, services like drug testing to monitor adherence are a challenge in this environment.

Video-observed oral fluid drug testing is non-invasive, easily observed and can be done conveniently in the patient's home, reducing their risk of exposure to COVID-19. The entire HIPAA-compliant process is conducted under video supervision by a remote Cordant collection specialist or by the clinician during a telemedicine appointment.

"Continuity of care is especially critical at this time as any disruption in addiction treatment, combined with the increased stress and uncertainty caused by the current pandemic, can increase the chance of relapse in this vulnerable population," said Sue Sommer, CEO and president of Cordant. "Being able to offer drug monitoring for telemedicine helps to continue to hold addiction patients accountable to their treatment program and offers clinicians an objective view into a patient's adherence during a time when they can't see the patient as often."

For patients taking buprenorphine, a medication used to treat opioid use disorder, Cordant's oral fluid test detects extremely low buprenorphine levels, which minimizes false-negative results and makes it a useful testing option for addiction and medication-assisted prescribers. Cordant also currently has one of the largest mental health testing menus, with the ability to test for 55 mental health medications using saliva.

To further enhance patient safety, Cordant offers a pharmacy solution that can help ensure patients have convenient and reliable access to buprenorphine. The medication can either be delivered to the patient's home or to the patient at the time of their visit to the clinic, reducing unnecessary travel. This program is also available for clinics using telemedicine for addiction treatment.

According to the Substance Abuse and Mental Health Services Administration (SAMHSA), Americans across the country will struggle with increases in depression, anxiety, trauma and grief. There is also an anticipated increase in substance misuse as lives are impacted for individuals and families.

SAMHSA and the Drug Enforcement Administration (DEA) have worked to offer flexibility in the prescribing and dispensing of controlled substances to ensure necessary addiction treatment remains accessible during this public health emergency. At this time, the DEA has announced that clinicians may prescribe controlled substances to patients using telemedicine without first conducting an in-person evaluation during this public health emergency.

"The COVID-19 pandemic has affected so much in our country today, and it hit addiction treatment patients as clinics made the hard choice to shut down or to find ways to safely care for their patients quickly," said Sommer. "It is rewarding to be able to offer services like our pharmacy program or our video drug testing that allow organizations to maintain a high level of treatment to their patients during this uncertain time."

To learn how to add Cordant's solution to your program, contact Cordant at [email protected] or 844-848-5955.

About Cordant Health Solutions®

Cordant Health Solutions® (www.cordantsolutions.com) provides innovative tools for monitoring behavioral health, chronic pain and criminal justice cases. Our unique pharmacy and drug testing programs provide accurate, actionable results to protect prescribers, hold patients accountable and optimize the quality of life.

As a leader in quality standards, Cordant is committed to developing solutions for payers, clinicians and organizations involved with substance use disorder, pain management and criminal justice agencies. Cordant is one of the only healthcare companies that offers monitoring and risk assessment tools through its innovative drug testing options and full-service, high-touch pharmacies, which specialize in the complex management and dispensing of controlled substances. 

Media Contact:
Tiffany Tuetken
303-570-4585
[email protected]

Related Images

cordant-health-solutions.jpg
Cordant Health Solutions

SOURCE Cordant Health Solutions


These press releases may also interest you

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

28 mar 2024
Discovery Silver Corp. ("Discovery" or the "Company") today announced financial results for the three and twelve months ended December 31, 2023 ("Q4 2023" and "2023", respectively). The Company also provided a summary of key events since the...

28 mar 2024
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...

28 mar 2024
The "Whole Genome and Exome Sequencing Markets by Application, Organism and Product with Executive and Consultant Guides. Includes Direct to Consumer Analysis. 2023 to 2027" report has been added to  ResearchAndMarkets.com's offering. Will all...

28 mar 2024
Boat Rocker Media Inc. ("Boat Rocker" or the "Company") , an independent, integrated global entertainment company, today reported its financial results for the three months ended December 31, 2023 ("fourth quarter" or "Q4") and for the year ended...



News published on and distributed by: